Cell Biotech, which leads the globalization of K-Probiotics by ranking No. 1 in global exports for 11 consecutive years, invited global pharmaceutical companies NOBEL and KALBE to tour probiotics production facilities. The event was designed to promote the excellence of Korean probiotics and to further strengthen global partnerships.
The event was held at the Cell Biotech plant in Gimpo, Gyeonggi-do, and involved pharmaceutical company officials and key doctors. NOBEL is a global pharmaceutical company headquartered in Türkiye and active in 22 countries in Europe and Asia. It has been in partnership with Cell Biotech for 12 years, serving as a bridgehead for exporting Korean probiotics to Türkiye and Eastern Europe. KALBE is the largest pharmaceutical company in Southeast Asia with an enterprise value of about $5.1 billion and annual sales of $1.9 billion, with 47 subsidiaries worldwide. It has been in partnership with Cell Biotech for 20 years.
Cell Biotech's Gimpo plant was established in 1995 and is the fifth in the world and the first in Korea to succeed in mass production of probiotics, opening the era of localization of probiotics. About 1,000 tons of probiotics are produced annually here, which is the birthplace of K-Probiotics. In particular, the R&D center is located together, so every production process, from the development of strains of Korean probiotics to research, fermentation, and relaxation, is one-stop. This is a prerequisite for the safety and stability of living probiotics and is the starting point of the premium "DUOLAC," Cell Biotech explained.
Through this field trip program, participants toured R&D, fermentation, and finished-dong in turn to see advanced production facilities of Korean probiotics. Global pharmaceutical companies said they were impressed by Cell Biotech's advanced technology and R&D capabilities and that they will explore various opportunities for global cooperation in the future.
"Cell Biotech is Korea's leading probiotics company and continues to promote global VIP visits and strengthen partnerships with global pharmaceutical companies to inform the world of the excellence of K-Probiotics," a Cell Biotech official said. "We will do our best to establish Korea as a bio powerhouse by leading the globalization of K-Probiotics and pioneering the global market with the Duolac brand."
Meanwhile, Cell Biotech's global field trip event has resumed since last year after it was suspended due to COVID-19, and more than 200 global officials from 12 countries participated in the field trip event last year and this year. The Gimpo plant said it is constantly receiving requests from pharmaceutical companies around the world for field trips as it presents global standards for lactobacillus production, including ▲GMP ▲ U.S. FDA GRAS ▲ ISO 9001 ▲ ISO14001 ▲ HACCP ▲ HALAL certification.